國家衛生研究院 NHRI:Item 3990099045/6050
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 855746      線上人數 : 1374
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6050


    題名: Resistance analysis and characterization of a thiazole analogue, BP008, as a potent hepatitis C virus NS5A inhibitor
    作者: Lin, HM;Wang, JC;Hu, HS;Wu, PS;Yang, CC;Wu, CP;Pu, SY;Hsu, TA;Jiaang, WT;Chao, YS;Chern, JH;Yeh, TK;Yueh, A
    貢獻者: Institute of Biotechnology and Pharmaceutical Research
    摘要: Hepatitis C virus (HCV) is a global health problem, affecting approximately 3% of the world's population. The standard treatment for HCV infection is often poorly tolerated and ineffective. Therefore, the development of novel or more effective treatment strategies to treat chronic HCV infection is urgently needed. In this report, BP008, a potent small-molecule inhibitor of HCV replication was developed from a class of compounds with thiazol core structure by means of utilizing a cell-based HCV replicon system. The compound reduced the reporter expression of the HCV1b replicon with an EC(50) and selective index value of 4.1 +/- 0.7 nM and >12,195, respectively. Sequencing analyses of several individual clones derived from BP008-resistant RNAs purified from cells harboring HCV1b replicon revealed that amino acid substitutions mainly within the N-terminal region (domain I) of NS5A were associated with decreased inhibitor susceptibility. Q24L, P58S and Y93H are the key substitutions for resistance selection; F149L and V153M play the compensatory role in the replication and drug resistance processes. Moreover, BP008 displayed synergistic effects with interferon alpha (IFN-alpha), NS3 protease inhibitor, and NS5B polymerase inhibitor, as well as good oral bioavailability in SD rats and favorable exposure in rat liver. In summary, our results presented an effective small-molecule inhibitor, BP008, potentially targeting at HCV NS5A. BP008 can be considered as part of a more effective therapeutic strategy for HCV in the future.
    日期: 2012-01
    關聯: Antimicrobial Agents and Chemotherapy. 2012 Jan;56(1):44-53.
    Link to: http://dx.doi.org/10.1128/aac.00599-11
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0066-4804&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000298404900006
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84455161734
    顯示於類別:[岳嶽] 期刊論文
    [葉燈光] 期刊論文
    [陳志豪] 期刊論文
    [趙宇生(2002-2013)] 期刊論文
    [蔣維棠] 期刊論文
    [徐祖安] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB22006008.pdf448KbAdobe PDF793檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋